Cargando…
Predicted number of peanut‐allergic patients needed to treat with epicutaneous immunotherapy (EPIT) to prevent one allergic reaction: A novel approach to assessing relevance
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291584/ https://www.ncbi.nlm.nih.gov/pubmed/34077581 http://dx.doi.org/10.1111/all.14973 |
| _version_ | 1784749170273288192 |
|---|---|
| author | Remington, Benjamin C. Koppelman, Stef J. Green, Todd D. Lack, Gideon Roberts, Graham Campbell, Dianne E. |
| author_facet | Remington, Benjamin C. Koppelman, Stef J. Green, Todd D. Lack, Gideon Roberts, Graham Campbell, Dianne E. |
| author_sort | Remington, Benjamin C. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9291584 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-92915842022-07-20 Predicted number of peanut‐allergic patients needed to treat with epicutaneous immunotherapy (EPIT) to prevent one allergic reaction: A novel approach to assessing relevance Remington, Benjamin C. Koppelman, Stef J. Green, Todd D. Lack, Gideon Roberts, Graham Campbell, Dianne E. Allergy Letters John Wiley and Sons Inc. 2021-06-19 2021-10 /pmc/articles/PMC9291584/ /pubmed/34077581 http://dx.doi.org/10.1111/all.14973 Text en © 2021 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
| spellingShingle | Letters Remington, Benjamin C. Koppelman, Stef J. Green, Todd D. Lack, Gideon Roberts, Graham Campbell, Dianne E. Predicted number of peanut‐allergic patients needed to treat with epicutaneous immunotherapy (EPIT) to prevent one allergic reaction: A novel approach to assessing relevance |
| title | Predicted number of peanut‐allergic patients needed to treat with epicutaneous immunotherapy (EPIT) to prevent one allergic reaction: A novel approach to assessing relevance |
| title_full | Predicted number of peanut‐allergic patients needed to treat with epicutaneous immunotherapy (EPIT) to prevent one allergic reaction: A novel approach to assessing relevance |
| title_fullStr | Predicted number of peanut‐allergic patients needed to treat with epicutaneous immunotherapy (EPIT) to prevent one allergic reaction: A novel approach to assessing relevance |
| title_full_unstemmed | Predicted number of peanut‐allergic patients needed to treat with epicutaneous immunotherapy (EPIT) to prevent one allergic reaction: A novel approach to assessing relevance |
| title_short | Predicted number of peanut‐allergic patients needed to treat with epicutaneous immunotherapy (EPIT) to prevent one allergic reaction: A novel approach to assessing relevance |
| title_sort | predicted number of peanut‐allergic patients needed to treat with epicutaneous immunotherapy (epit) to prevent one allergic reaction: a novel approach to assessing relevance |
| topic | Letters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291584/ https://www.ncbi.nlm.nih.gov/pubmed/34077581 http://dx.doi.org/10.1111/all.14973 |
| work_keys_str_mv | AT remingtonbenjaminc predictednumberofpeanutallergicpatientsneededtotreatwithepicutaneousimmunotherapyepittopreventoneallergicreactionanovelapproachtoassessingrelevance AT koppelmanstefj predictednumberofpeanutallergicpatientsneededtotreatwithepicutaneousimmunotherapyepittopreventoneallergicreactionanovelapproachtoassessingrelevance AT greentoddd predictednumberofpeanutallergicpatientsneededtotreatwithepicutaneousimmunotherapyepittopreventoneallergicreactionanovelapproachtoassessingrelevance AT lackgideon predictednumberofpeanutallergicpatientsneededtotreatwithepicutaneousimmunotherapyepittopreventoneallergicreactionanovelapproachtoassessingrelevance AT robertsgraham predictednumberofpeanutallergicpatientsneededtotreatwithepicutaneousimmunotherapyepittopreventoneallergicreactionanovelapproachtoassessingrelevance AT campbelldiannee predictednumberofpeanutallergicpatientsneededtotreatwithepicutaneousimmunotherapyepittopreventoneallergicreactionanovelapproachtoassessingrelevance |